Serum and urine malondialdehyde levels in NIDDM patients with and without hyperlipidemia.

Malondialdehyde (MDA), a marker of lipid peroxidation, was measured as thiobarbituric acid reactive substance (TBARS) in 78 noninsulin-dependent diabetic patients, 38 hyperlipidemic patients, and 28 healthy subjects. Diabetic patients were divided into groups and subgroups according to the existence of hyperlipidemia and other complications. Serum and urine MDA concentrations were significantly higher in diabetic and nondiabetic patient groups than in the control group. By contrast to urine MDA levels, serum MDA level was significantly higher in hyperlipidemic diabetics than that of normolipidemic diabetics. Serum MDA levels in the hyperlipidemic diabetic group and urine MDA levels in both diabetic groups were significantly higher than those in hyperlipidemic nondiabetic group. In both diabetic groups, the existence of complications didn't affect serum and urine MDA levels. No correlation existed between serum and urine MDA levels in both patient groups and control subjects. This study confirmed the existence of lipid peroxidation disorders in diabetic patients.

Plasma and urine sialic acid in non-insulin dependent diabetes mellitus.

Urinary excretions of albumin, glycosaminoglycans (GAGS), total sialic acid (TSA), and lipid associated sialic acid (LASA) were measured in 78 non-insulin dependent diabetic patients (NIDDM) and 28 healthy subjects. TSA excretion was significantly higher in normoalbuminuric and microalbuminuric diabetic subjects than the control subjects and TSA excretion was correlated with urinary albumin excretion rate (AER). In normoalbuminuric diabetics, the duration of diabetes correlated significantly with both sialicaciduria and albuminuria. Although serum TSA levels were significantly higher in both diabetic groups than the control subjects, there was no correlation between serum and urinary TSA levels.

Plasma and urine malondialdehyde levels in non-insulin-dependent diabetic patients with and without microalbuminuria.

Malondialdehyde, a marker of lipid peroxidation, was measured as thiobarbituric acid-reactive substance in 78 non-insulin-dependent diabetic patients and 28 healthy subjects. Patients were divided into groups and subgroups according to the presence of microalbuminuria and other complications. Plasma and urine malondialdehyde concentrations were significantly higher in patients with and without microalbuminuria than in controls. In contrast to urine malondialdehyde, plasma malondialdehyde levels were significantly higher in microalbuminuric diabetes than in the normolbuminuric diabetic group. There was no correlation between malondialdehyde concentration and glycemic control. This study confirmed the existence of lipid peroxidation disorders in diabetic patients.